Helix Acquisition Corp. II Cl A (HLXB)

$10.49 +0.14 (1.35%)
Market Cap 190.44M
Revenue (ttm) 0.00
Net Income (ttm) -41,692.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 100
Avg Vol 10,912
Day's Range N/A - N/A
Shares Out 18.40M
Stochastic %K 25%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Helix Acquisition Corp. II focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is based in Boston, Massachusetts.

Industry: Shell Companies
Sector: Financial Services
Phone: 857-702-0370
Address:
200 Clarendon Street, 52nd Floor, Boston, United States
Latest News on HLXB
BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition

Aug 11, 2025, 4:30 PM EDT - 13 days ago

BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition

BBOT

Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics

Aug 6, 2025, 7:33 AM EDT - 18 days ago

Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics

Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registration Statement for Proposed Business Combination

Jul 11, 2025, 7:43 AM EDT - 6 weeks ago

Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registration Statement for Proposed Business Combination

BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines

Feb 28, 2025, 7:49 AM EST - 6 months ago

BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines

Helix Acquisition Corp. II Announces Closing of $184 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares

Feb 14, 2024, 7:30 AM EST - 1 year ago

Helix Acquisition Corp. II Announces Closing of $184 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares